Histone deacetylases (HDAC) have been implicated in prostate cancer progression, providing the rationale for pharmacological treatment of the disease with HDAC inhibitors (HDACi) (Abbas and Gupta, 2008). This evidence concerns the gene HDAC9 and prostate carcinoma.